Chemoprevention

Jun Cheon

doi:10.5124/jkma.2004.47.5.441

J Korean Med Assoc > Volume 47(5); 2004 > Article

Cheon: Chemoprevention

Special Issue

Prostate Cancer

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2004; 47(5): 441-445.

Published online: May 31, 2004

DOI: http://dx.doi.org/10.5124/jkma.2004.47.5.441

Chemoprevention

Jun Cheon, M.D.

Department of Urology, Korea University College of Medicine & Hospital, Korea. jcheon@kumc.or.kr

Abstract

Despite advance in detection and management of prostate cancer, this disease remains a major cause of morbidity and mortality in men. Increasing attention has focused on the role of chemoprevention for prostate cancer, ie the administration of agents that inhibit one or more steps in the natural history of prostate carcinogenesis. Chemoprevention of prostate cancer is currently being tested in a wide range of clinical trials, and have focused on the role of dietary factors, vitamins and trace elements in prostate cancer. These studies have the potential to fundamentally alter the current approach to prostate cancer management. The current status of clinical trials investigating the use of interventions designed to reduce the risk of prostate cancer is reviewed.

Prostate cancer; Chemoprevention

References

1. Akazaki K, Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst 1973;50:1137-1144.

2. Thomson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride in the development of prostate cancer. N Engl J Med 2003;349:215-224.

3. Gaynor ML. Isoflavones and the prevention and treatment of prostate disease: is there a role? Cleveland Clin J Med 2003;70:203-204.

4. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998;90:1637-1647.

5. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels:results of the prospective analysis. Cancer Res 1999;59:1225-1230.

6. Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp Biol Med 2002;227:920-923.

7. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toe nails and the risk of advanced prostatic cancer. J Natl Cancer Inst 1998;90:1219-1224.

8. Klein EA, Thompson IM, Lippman SM, Goodman Pj, Albanes D, Taylor PR, et al. SELECT: the next prostate cancer prevention trial. J Urol 2001;166:1311-1315.

9. Robert RO, Jacobson DJ, Lieber MM, Jacobson SJ, Girman CJ, Rhodes T. Prostate cancer and non-steroidal anti-inflammatory drugs:a prospective association. J Urol suppl 2001;165:256. 62, abstract.

10. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D:Regulation of target gene expression. J Cell Biochem 2003;88:363-371.